...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >Levonorgestrel-releasing intrauterine system--the discontinuing story.
【24h】

Levonorgestrel-releasing intrauterine system--the discontinuing story.

机译：左炔诺孕酮释放子宫系统-停产的故事。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Levonorgestrel-releasing Intrauterine System (LNG-IUS) is licensed for use as a contraceptive, for the treatment of heavy menstrual bleeding and during estrogen replacement therapy. It is publicized as a local source of progestogen with minimal systemic adverse effects. However, there is overwhelming evidence of elevated serum and tissue levels of levonorgestrel, and high discontinuation and dissatisfaction rates amongst users. The guidelines of The National Institute for Health and Clinical Excellence (NICE), United Kingdom recommended that the healthcare professionals should be aware that upto 60% of women discontinue using LNG-IUS within 5 years because of unscheduled bleeding, pain, and/or systemic progestogenic adverse effects. This article highlights these issues to healthcare professionals to ensure that the rates of adverse effects are not underestimated, and full information are made available to women to enable them making an informed choice.
机译：左炔诺孕酮释放子宫内系统（LNG-IUS）已获许可用作避孕药具，用于治疗月经大量出血和雌激素替代治疗期间。它被公布为孕激素的局部来源，对全身的不良影响最小。然而，有绝大多数证据表明左炔诺孕酮的血清和组织水平升高，并且使用者中止和不满意率很高。英国国家卫生与临床卓越研究所（NICE）的指南建议医疗保健专业人员应注意，由于计划外出血，疼痛和/或全身性出血，多达60％的妇女在5年内停止使用LNG-IUS孕激素的不良反应。本文向医疗保健专业人员强调了这些问题，以确保不会低估不良反应的发生率，并且向妇女提供了充分的信息，使她们能够做出明智的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号